熱門資訊> 正文
FDA批准Hydros前列腺治疗,程序跳跃
2024-08-21 22:42
- Shares of PROCEPT BioRobotics (NASDAQ:PRCT) gained on Wednesday morning after the surgical robotics company announced the FDA clearance of its HYDROS Robotic System as a therapy for benign prostatic hyperplasia (BPH), a noncancerous enlargement of the prostate gland.
- The San Jose, California-based medical device company said that the FDA issued the AI-powered platform the agency's 510(k) clearance, paving the way for its U.S. launch.
- HYDROS Robotic System is designed to deliver aquablation therapy for BPH using real-time ultrasound imaging and cystoscopy data.
- With a multidimensional view of the prostate, surgeons can provide patients with a personalized treatment option to provide relief without impacting their sexual function or continence.
- Despite its intentions to begin a full-market release of HYDROS in the current quarter, the company reiterated its previously issued financial guidance for the year.
More on Procept
- PROCEPT BioRobotics Corporation (PRCT) Q2 2024 Earnings Call Transcript
- Seeking Alpha’s Quant Rating on Procept
- Historical earnings data for Procept
- Financial information for Procept
風險及免責提示:以上內容僅代表作者的個人立場和觀點,不代表華盛的任何立場,華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前,應結合自身情況,考慮投資產品的風險。必要時,請諮詢專業投資顧問的意見。華盛不提供任何投資建議,對此亦不做任何承諾和保證。